The Effects of Natural Epigenetic Therapies in 3D Ovarian Cancer and Patient-Derived Tumor Explants: New Avenues in Regulating the Cancer Secretome.
natural epigenetic compounds
organoids
ovarian cancer
secretome
spheroids
tumor microenvironment
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
received:
04
05
2023
revised:
26
06
2023
accepted:
27
06
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
High mortality rates in ovarian cancer have been linked to recurrence, metastasis, and chemoresistant disease, which are known to involve not only genetic changes but also epigenetic aberrations. In ovarian cancer, adipose-derived stem cells from the omentum (O-ASCs) play a crucial role in supporting the tumor and its tumorigenic microenvironment, further propagating epigenetic abnormalities and dissemination of the disease. Epigallocatechin gallate (EGCG), a DNA methyltransferase inhibitor derived from green tea, and Indole-3-carbinol (I3C), a histone deacetylase inhibitor from cruciferous vegetables, carry promising effects in reprograming aberrant epigenetic modifications in cancer. Therefore, we demonstrate the action of these diet-derived compounds in suppressing the growth of 3D ovarian cancer spheroids or organoids as well as post-treatment cancer recovery through proliferation, migration, invasion, and colony formation assays when compared to the synthetic epigenetic compound Panobinostat with or without standard chemotherapy. Finally, given the regulatory role of the secretome in growth, metastasis, chemoresistance, and relapse of disease, we demonstrate that natural epigenetic compounds can regulate the secretion of protumorigenic growth factors, cytokines, extracellular matrix components, and immunoregulatory markers in human ovarian cancer specimens. While further studies are needed, our results suggest that these treatments could be considered in the future as adjuncts to standard chemotherapy, improving efficiency and patient outcomes.
Identifiants
pubmed: 37509102
pii: biom13071066
doi: 10.3390/biom13071066
pmc: PMC10377145
pii:
doi:
Substances chimiques
Tea
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Natl Toxicol Program Tech Rep Ser. 2017 Jul;(584):
pubmed: 33540959
Clin Epigenetics. 2021 Apr 20;13(1):83
pubmed: 33879235
Molecules. 2019 Aug 09;24(16):
pubmed: 31404982
Chem Biol Interact. 2010 Aug 5;186(3):255-66
pubmed: 20570586
Oncogene. 2018 Jul;37(29):3981-3997
pubmed: 29662190
Biomolecules. 2021 Nov 17;11(11):
pubmed: 34827710
Int J Mol Sci. 2019 Sep 11;20(18):
pubmed: 31514474
Gynecol Oncol Rep. 2017 Mar 21;20:81-86
pubmed: 28378010
Nat Biotechnol. 2010 Oct;28(10):1069-78
pubmed: 20944599
Mol Pharmacol. 2005 Oct;68(4):1018-30
pubmed: 16037419
Int J Mol Sci. 2020 Nov 19;21(22):
pubmed: 33228245
Gynecol Oncol. 2012 Sep;126(3):491-8
pubmed: 22564714
PLoS One. 2012;7(5):e38340
pubmed: 22666502
Cancer. 2011 Apr 15;117(8):1661-9
pubmed: 21472713
Curr Top Med Chem. 2016;16(7):680-96
pubmed: 26303417
Cancer Lett. 2016 Jul 28;377(2):174-82
pubmed: 27131957
Trends Immunol. 2019 Feb;40(2):142-158
pubmed: 30639050
J Hematol Oncol. 2020 Oct 15;13(1):136
pubmed: 33059744
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Epigenetics. 2012 Apr;7(4):350-60
pubmed: 22419067
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Cancer. 2011 Oct 1;117(19):4424-38
pubmed: 21491416
J Nutr. 2004 Dec;134(12 Suppl):3493S-3498S
pubmed: 15570059
Clin Cancer Res. 2012 Feb 1;18(3):771-82
pubmed: 22167410
Carcinogenesis. 2011 Apr;32(4):537-44
pubmed: 21209038
Cytokine. 2012 Jul;59(1):145-55
pubmed: 22579115
J Ovarian Res. 2016 Sep 15;9(1):58
pubmed: 27633667
Am J Obstet Gynecol. 2009 Feb;200(2):177.e1-9
pubmed: 19110234
Am J Obstet Gynecol. 2004 Nov;191(5):1552-72
pubmed: 15547525
PLoS One. 2013 Dec 02;8(12):e81859
pubmed: 24312594
Expert Opin Investig Drugs. 2010 Nov;19(11):1339-54
pubmed: 20815774
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80
pubmed: 12768623
Cancer Res. 2015 Apr 1;75(7):1161-8
pubmed: 25736688
Science. 2014 Jul 18;345(6194):1247125
pubmed: 25035496
Biomolecules. 2020 Oct 25;10(11):
pubmed: 33113766
Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584
pubmed: 32636524
Cancer Lett. 2008 Apr 18;262(2):153-63
pubmed: 18314259
Front Oncol. 2022 Jan 03;11:796588
pubmed: 35047406
Biochimie. 2013 Dec;95(12):2222-8
pubmed: 23770442
Nutrients. 2023 Jan 09;15(2):
pubmed: 36678191
Cancer Microenviron. 2018 Dec;11(2-3):115-124
pubmed: 30039195
Drug Des Devel Ther. 2020 Oct 12;14:4245-4250
pubmed: 33116412
Cancer Res. 2003 Nov 15;63(22):7563-70
pubmed: 14633667
Int J Gynaecol Obstet. 2019 May;145(2):225-232
pubmed: 30828803
Nat Rev Cancer. 2019 Mar;19(3):151-161
pubmed: 30723290
BMC Cancer. 2018 Sep 20;18(1):904
pubmed: 30236079
Genes (Basel). 2019 Feb 23;10(2):
pubmed: 30813436
J Cell Biochem Suppl. 1997;28-29:111-6
pubmed: 9589355
F1000Res. 2018 Jun 1;7:
pubmed: 29904587
Cancer Biol Ther. 2014 Sep;15(9):1256-67
pubmed: 24972095
PLoS One. 2016 Jun 28;11(6):e0158208
pubmed: 27352023
Expert Rev Anticancer Ther. 2010 Jan;10(1):47-60
pubmed: 20014885
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Reproduction. 2015 Aug;150(2):R55-64
pubmed: 25918438
Genes Nutr. 2012 Jul;7(3):357-67
pubmed: 22328271
Nutrients. 2012 Nov 08;4(11):1679-91
pubmed: 23201840
Gynecol Oncol. 2010 Feb;116(2):195-201
pubmed: 19854495
Cancers (Basel). 2019 Jul 03;11(7):
pubmed: 31277278
Int J Oncol. 2022 May;60(5):
pubmed: 35315502
Front Immunol. 2011 Jul 21;2:29
pubmed: 22566819
Curr Pharmacol Rep. 2015 Feb 1;1(1):46-51
pubmed: 25774338
Clin Epigenetics. 2019 Jan 15;11(1):7
pubmed: 30646939
Trends Cancer. 2020 Jun;6(6):489-505
pubmed: 32460003
Endocr Relat Cancer. 1999 Mar;6(1):93-107
pubmed: 10732792